A detailed Breast Recurrence Score® report is generated for each patient containing a Recurrence Score® result
A quantitative score, based on a continuous scale of 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient
Assesses the 9-year risk of distant recurrence in node-negative patients1
5-year distant recurrence or mortality in node-positive patients2
Likelihood that chemotherapy will benefit your patient3,4
The relevance of the ER score by RT-PCR
A strong predictor of tamoxifen benefit in node-negative patients
While the Recurrence Score result and corresponding average rate of distant recurrence accounts for this effect of tamoxifen (in addition to the tumor’s fundamental prognosis), the single-gene ER score may also help clarify the magnitude of tamoxifen benefit.5
How your patient's score is generated
The Breast Recurrence Score test is a genomic test that measures the expression of cancer-related genes in your patient’s tumor. Your patient’s score is based on the expression of 21 specific genes from tumor tissue removed during the surgery or core biopsy. Looking at the expression of this unique set of genes, the score provides important information about how likely your patient’s cancer is to return and the likelihood of benefit, or not, from chemotherapy.
Breakdown of the 21 genes included in the assay:
|16 Breast Cancer-Related Genes|
|5 Reference Genes|
Getting the results
Most Breast Recurrence Score reports are available within 2 weeks from the date the specimen is received in the Exact Sciences lab. You can access the results through the online physician portal or receive the report by fax.
Here's how to order